Fig. 7.

The tAPC strategy is effective in multiple tumor models. (A) MC38 cells could be transfected in vitro and in vivo after i.t. injection with nanoparticles. (B) Transfected MC38 cells show the same trends in activating splenocytes as B16-F10 cells, with a synergistic effect seen between signals 2 and 3. For each time point (red and blue), one-way ANOVA was done with Dunnett posttests comparing to “Ctrl.” ***P < 0.001, ****P < 0.0001. (C) MC38 tumors grew more slowly after tAPC nanoparticle treatment. Statistically significant differences in the growth rate were measured by two-way repeated-measures t tests with Holm–Sidak tests to correct for multiple comparisons. *P < 0.05. (D) 41BBL/IL12 NPs + αPD1-treated mice survived significantly longer than control NPs + αPD1-treated mice and are also able to 100% reject a rechallenge of the tumor on the opposite flank. Differences in survival were calculated by the Mantel–Cox log-rank test with Bonferroni correction for multiple comparisons.